Nexalin Technology's Major Compliance Achievement
Nexalin Technology, Inc. (the "Company" or "Nexalin") recently announced an important update regarding its status with The Nasdaq Stock Market. The Company received a notification indicating it has successfully regained compliance with Nasdaq's minimum bid price requirement. This achievement was communicated to the Company, and it marks a significant milestone in Nexalin's journey.
Significant Progress in Non-Invasive Treatments
The CEO of Nexalin, Mark White, expressed enthusiasm about this development. He stated, "Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need." He highlighted the importance of this achievement in enhancing shareholder value and the Company’s visibility among investors, particularly as it advances clinical research and regulatory approvals globally.
Nexalin’s Mission
Nexalin has a strong commitment to reshaping the treatment landscape for mental health and neurological disorders. The company is dedicated to developing innovative solutions aimed at addressing the global mental health epidemic. With its state-of-the-art neurostimulation products, Nexalin aims to offer relief to individuals suffering from mental health issues.
Innovative Neurostimulation Technology
Nexalin's products utilize bioelectronic medical technology designed to target deep structures in the mid-brain associated with mental health disorders. The unique features of the Nexalin neurostimulation devices allow them to deliver treatments that are believed to be non-invasive and undetectable to the human body.
Global Reach and Approvals
The company's Nexalin Gen-2 15 milliamp neurostimulation device has gained approval in select international markets, including China, Brazil, and Oman. This global outreach emphasizes Nexalin’s commitment to making mental health treatments available to a broader audience. With ongoing advancements and potential future approvals, the company continues to establish itself as a leader in the neurostimulation field.
Commitment to Shareholders
As Nexalin advances in its mission, it remains deeply appreciative of the support from its shareholders. The leadership recognizes that this backing is pivotal as the Company navigates the challenges of bringing these innovative treatments to market. Continued compliance with Nasdaq is anticipated to bolster investor confidence and enhance market engagement.
Contact Information
For more insights into Nexalin’s cutting-edge developments and product offerings, interested parties can reach out to their communication representatives. Crescendo Communications, LLC can be contacted at (212) 671-1020 or via email at NXL@crescendo-ir.com.
Frequently Asked Questions
What recent achievement did Nexalin Technology announce?
Nexalin Technology announced that it has regained compliance with Nasdaq's minimum bid price requirement.
What is the significance of this compliance for Nexalin?
This compliance is a critical milestone that underscores the company's commitment to its mission and enhances its visibility among investors.
What type of products does Nexalin Technology develop?
Nexalin develops innovative neurostimulation products aimed at treating mental health issues non-invasively.
In which countries has Nexalin's Gen-2 device received approval?
Nexalin's Gen-2 neurostimulation device has been approved in China, Brazil, and Oman.
Who can be contacted for more information about Nexalin?
For inquiries, Crescendo Communications can be contacted at (212) 671-1020 or through email at NXL@crescendo-ir.com.
